BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28766792)

  • 1. Will growth in cryptomarket drug buying increase the harms of illicit drugs?
    Aldridge J; Stevens A; Barratt MJ
    Addiction; 2018 May; 113(5):789-796. PubMed ID: 28766792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hidden wholesale: The drug diffusing capacity of online drug cryptomarkets.
    Aldridge J; Décary-Hétu D
    Int J Drug Policy; 2016 Sep; 35():7-15. PubMed ID: 27260863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing cryptomarkets for drugs. A characterisation of sellers and buyers over time.
    Tzanetakis M
    Int J Drug Policy; 2018 Jun; 56():176-186. PubMed ID: 29449105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safer scoring? Cryptomarkets, social supply and drug market violence.
    Barratt MJ; Ferris JA; Winstock AR
    Int J Drug Policy; 2016 Sep; 35():24-31. PubMed ID: 27241015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors.
    Van Hout MC; Hearne E
    Int J Drug Policy; 2017 Feb; 40():102-110. PubMed ID: 28027812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reputation transferability across contexts: Maintaining cooperation among anonymous cryptomarket actors when moving between markets.
    Norbutas L; Ruiter S; Corten R
    Int J Drug Policy; 2020 Feb; 76():102635. PubMed ID: 31972474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between cryptomarket drug purchase, social networks and adverse drug events: A cross-sectional study.
    Coney L; Peacock A; Malm A; Munksgaard R; Aldridge J; Ferris JA; Maier LJ; Winstock AR; Barratt MJ
    Int J Drug Policy; 2024 Jan; 123():104258. PubMed ID: 38056221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery dilemmas: How drug cryptomarket users identify and seek to reduce their risk of detection by law enforcement.
    Aldridge J; Askew R
    Int J Drug Policy; 2017 Mar; 41():101-109. PubMed ID: 28089207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'What if you live on top of a bakery and you like cakes?'-Drug use and harm trajectories before, during and after the emergence of Silk Road.
    Barratt MJ; Lenton S; Maddox A; Allen M
    Int J Drug Policy; 2016 Sep; 35():50-7. PubMed ID: 27157539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Nice people doing shady things': Drugs and the morality of exchange in the darknet cryptomarkets.
    Masson K; Bancroft A
    Int J Drug Policy; 2018 Aug; 58():78-84. PubMed ID: 29870962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forensic drug intelligence and the rise of cryptomarkets. Part I: Studying the Australian virtual market.
    Broséus J; Morelato M; Tahtouh M; Roux C
    Forensic Sci Int; 2017 Oct; 279():288-301. PubMed ID: 28927690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmedical prescription psychiatric drug use and the darknet: A cryptomarket analysis.
    Cunliffe J; Décary-Hêtu D; Pollak TA
    Int J Drug Policy; 2019 Nov; 73():263-272. PubMed ID: 30772109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harms, benefits and the policing of cryptomarkets: a response to commentaries.
    Aldridge J; Stevens A; Barratt MJ
    Addiction; 2018 May; 113(5):802-804. PubMed ID: 29468766
    [No Abstract]   [Full Text] [Related]  

  • 14. Should we smoke it for you as well? An ethnographic analysis of a drug cryptomarket environment.
    Kowalski M; Hooker C; Barratt MJ
    Int J Drug Policy; 2019 Nov; 73():245-254. PubMed ID: 31054880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing market competition and vendors' size and scope on AlphaBay.
    Paquet-Clouston M; Décary-Hétu D; Morselli C
    Int J Drug Policy; 2018 Apr; 54():87-98. PubMed ID: 29414490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. #Drugsforsale: An exploration of the use of social media and encrypted messaging apps to supply and access drugs.
    Moyle L; Childs A; Coomber R; Barratt MJ
    Int J Drug Policy; 2019 Jan; 63():101-110. PubMed ID: 30530252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forensic drug intelligence and the rise of cryptomarkets. Part II: Combination of data from the physical and virtual markets.
    Morelato M; Broséus J; De Grazia A; Tahtouh M; Esseiva P; Roux C
    Forensic Sci Int; 2018 Jul; 288():201-210. PubMed ID: 29763810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An island apart? Risks and prices in the Australian cryptomarket drug trade.
    Cunliffe J; Martin J; Décary-Hétu D; Aldridge J
    Int J Drug Policy; 2017 Dec; 50():64-73. PubMed ID: 29055855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Illicit drug prices and quantity discounts: A comparison between a cryptomarket, social media, and police data.
    Moeller K; Munksgaard R; Demant J
    Int J Drug Policy; 2021 May; 91():102969. PubMed ID: 33041184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Offline constraints in online drug marketplaces: An exploratory analysis of a cryptomarket trade network.
    Norbutas L
    Int J Drug Policy; 2018 Jun; 56():92-100. PubMed ID: 29621742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.